Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Betaseron: SHR will begin in the second half of 2002 an international, blinded Phase III BEYOND trial in more than 2,000 RRMS patients evaluating 250 µg of Beta

Schering AG (SHR; FSE:SCH), Berlin, Germany
Product: Betaseron
Business: Neurological

Read the full 104 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers